ArticleJournal of translational medicine2026
A contamination-adjusted tissue thrombopoietic framework identifies a clinically relevant CAF-myeloid niche in non-small cell lung cancer: a paired transcriptomic and survival study.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlatelet-related cancer biology is often studied through circulating markers, yet tissue-centered thrombopoietic programs in lung cancer remain poorly defined and are vulnerable to blood-contamination artifacts. We developed a contamination-adjusted megakaryopoiesis-platelet tumor axis (MPTA) framework to test whether thrombopoietic activity in lung cancer is embedded in a stromal-myeloid niche with clinical relevance.
methodsWe used paired bulk RNA sequencing from a local cohort of 99 tumor-adjacent pairs as the discovery engine. After paired differential expression and explicit adjustment for blood-contamination structure, a locked tissue-centered MPTA score was evaluated using public single-cell, bulk, spatial, and platelet-transcript reference layers together with de-identified local clinicopathologic and survival data.
resultsPaired analysis identified a tumor-enriched contamination-adjusted MPTA, which remained significantly higher in tumors than in adjacent tissues after correction (0.34 vs -0.26; p = 1.4 × 10^-5). Direct public single-cell scoring together with bulk back-projection and supportive spatial analyses localized the composite signal primarily to a CAF-myeloid niche, while tumor epithelial cells contributed more selectively to the tumor-thrombopoietic component rather than dominating the composite signal. The strongest translational signal was observed locally, where tumor_MPTA was retained as the primary prognostic readout and predicted worse overall survival (hazard ratio 1.43, 95% confidence interval 1.15-1.78; p = 0.00144), whereas delta_MPTA was retained only as a supportive within-patient metric because of proportional-hazards sensitivity in fully adjusted models. External TCGA analyses preserved tumor-normal directionality but provided only limited, non-confirmatory prognostic support, and platelet transcriptomes did not recapitulate the tissue-derived program.
conclusionsA contamination-adjusted, tissue-centered MPTA framework supports a clinically relevant CAF-myeloid thrombopoietic niche in lung cancer. For clinical interpretation, tumor_MPTA-not delta_MPTA-should be regarded as the primary prognostic readout. The strongest evidence comes from paired human tissue and local survival analyses, whereas the external layers are supportive rather than confirmatory, and platelet transcriptomes define a biological boundary rather than a validation layer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.